New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
07:32 EDTPOZNPOZEN submits PA8140/PA32540 Phase 1 final study report
POZEN announced that they have submitted the final study report for the Phase 1 study comparing the pharmacokinetic profile of the omeprazole component of PA8140 tablets to that of PA32540 tablets as agreed with the U.S. Food and Drug Administration.
News For POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
13:20 EDTPOZNPOZEN, Tribute complete combination to create Aralez Pharmaceuticals
Subscribe for More Information
February 2, 2016
09:04 EDTPOZNPOZEN's stockholders approved merger with Tribute Pharma Canada
POZEN announced that its stockholders approved the Agreement and Plan of Merger and Arrangement with Tribute Pharmaceuticals Canada and the carrying out of the transactions contained therein. Upon closing of the transaction, the POZEN and Tribute businesses will operate as subsidiaries of Aralez Pharmaceuticals, a company domiciled in Canada. The Merger Agreement was also adopted by the Tribute shareholders on February 1. The proposed transaction remains subject to certain conditions and approvals, including approval of the Ontario Superior Court of Justice, listing of Aralez shares and customary closing conditions, and is expected to occur promptly following satisfaction of all conditions. Aralez will be listed on the NASDAQ stock exchange under the ticker symbol "ARLZ" and is expected to begin trading on or about February 8 and will be listed on the Toronto Stock Exchange under the ticker symbol "ARZ" and is expected to begin trading on on or about February 10, assuming closing on February 5.
February 1, 2016
14:49 EDTPOZNPOZEN to host special shareholder meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use